Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bentracimab - SFJ Pharmaceuticals

Next Previous
Drug Profile

Bentracimab - SFJ Pharmaceuticals

Alternative Names: MEDI-2452; PB-2452

Latest Information Update: 13 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer PhaseBio Pharmaceuticals; SFJ Pharmaceuticals
  • Class Antibodies; Antihaemorrhagics; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Platelet aggregation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemorrhage

Most Recent Events

  • 13 Jan 2025 Bentracimab is still in phase III REVERSE-IT trial for Haemorrhage (In adults, In the elderly) in the USA, Sweden, Spain, Switzerland, Canada, Austria, Germany, Belgium and the United Kingdom (NCT04286438) (EudraCT2019-004457-92)
  • 06 Jan 2025 Bentracimab is still in phase III REVERSE-IT trial for Haemorrhage (In adults, In the elderly) in the China, France, Italy, Netherlands, (IV, Infusion) (NCT04286438) (EudraCT2019-004457-92)
  • 09 Sep 2024 SFJ Pharmaceuticals completes the phase III REVERSE-IT trial for Haemorrhage (In adults, In the elderly) in the UK, US, Austria, Belgium, Canada, China, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland (IV, Infusion) (NCT04286438) (EudraCT2019-004457-92)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top